Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2022
August 23, 2022 at 03:16 pm IST
Share
Getein Biotech, Inc reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 971.3 million compared to CNY 595.42 million a year ago. Revenue was CNY 973.21 million compared to CNY 600.29 million a year ago.
Net income was CNY 329.8 million compared to CNY 170.86 million a year ago. Basic earnings per share from continuing operations was CNY 0.65 compared to CNY 0.34 a year ago. Diluted earnings per share from continuing operations was CNY 0.65 compared to CNY 0.34 a year ago.
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
GETEIN BIOTECH, INC 
